ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mouse Models, Other"

  • Abstract Number: 1905 • ACR Convergence 2020

    Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis

    Yuzuru Yamamoto1, Takaichi Okano2, Takumi Nagamoto2, Yoshikazu Fujikawa3, Yoshihide Ichise2, Hirotaka Yamada2, Ikuko Naka2, Yo Ueda4, Kengo Akashi5, Sho Sendo6, Akira Onishi5, Jun Saegusa7 and Akio Morinobu5, 1Kobe University, Kobe-city, Japan, 2Kobe University, Kobe, Japan, 3Kobe University, Kobe city, Japan, 4Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 5Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, 6Kobe University, Kobe, 7Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and…
  • Abstract Number: 1912 • ACR Convergence 2020

    Novel Role of Thy-1 (CD90) in the Pathogenesis of Skin Fibrosis

    Roberta Goncalves Marangoni1, Stacey Duemmel2, Marc Nuzzo2, Ananta Paine1, Christopher Ritchlin3 and Benjamin Korman3, 1University of Rochester Medical Center, Rochester, NY, 2Department of Medicine, University of Rochester Medical Center, Rochester, 3Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Thy-1 (CD90) is a GPI-anchored cell surface protein that is highly expressed in subsets of fibroblasts. Previous work has shown that Thy-1 deficiency exacerbates…
  • Abstract Number: 1916 • ACR Convergence 2020

    KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

    Marta Del Rio Oliva1, Michael Basler1, Darrin Bomba2, Diana Lam2, Jennifer Brandl2, Christopher Kirk2 and Marcus Groettrup1, 1University of Konstanz, Konstanz, Germany, 2Kezar Life Sciences, Inc, San Francisco, CA

    Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…
  • Abstract Number: 1969 • ACR Convergence 2020

    The Dynamics of Macrophage Sub-Populations in the Inflammatory Phase Following Joint Trauma

    Samuel Hamilton1, Anna Montgomery1, Niamh Fahy2, Maximilian Mayr1, Shang-Yang Chen1, Gaurav Gadhvi1, Yvonne Bastiaansen-Jenniskens2 and Deborah Winter3, 1Northwestern University, Chicago, IL, 2Erasmus MC, Rotterdam, Netherlands, 3Northwestern University Division of Rheumatology, Chicago, IL

    Background/Purpose: Macrophages fulfill critical functions in maintaining tissue homeostasis in steady-state, as well as in inflammation and immune response.  In the joint synovium, we have…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology